European Journal of Gastroenterology & Hepatology · 2007 · 58 citations · 34 references
Veterinary MedicineImmunologyPharmacotherapyImmunopathologyImmunotherapyInflammationGastrointestinal InflammationImmune-mediated Inflammatory DiseasesInflammatory BiomarkersInflammatory Bowel DiseaseInflammatory Disease PharmacotherapyMetabolic InflammationColonic InflammationDisease Activity MeasurementEnzyme-linked Immunosorbent Assay (Elisa)Inflammation-related BiomarkersInflammatory Bowel Disease PathophysiologyInflammatory Bowel Disease TherapyProinflammatory MediatorsTumor Necrosis Factor Therapy
BACKGROUND: Tumour necrosis factor alpha is a critical mediator of inflammation-related altered metabolism in inflammatory bowel disease (IBD), possibly through its interaction with adipokines, which play an important role in IBD. Infliximab is a well established antitumour necrosis factor alpha treatment in IBD. AIM AND METHODS: We studied serum levels of leptin, adiponectin and resistin in 20 IBD patients before and after infliximab treatment using commercially available enzyme-linked immunosorbent assays. The results were correlated with alterations of disease activity, BMI and C-reactive protein. RESULTS: Infliximab induced clinical response or remission in 18 out of 20 treated IBD patients. Mean serum-leptin levels were 4.6+/-0.5 and 5.1+/-0.5 ng/ml (P=0.41), mean serum-adiponectin levels were 10513.9+/-1216.9 and 9653.5+/-1031.5 ng/ml (P=0.36) and mean serum-resistin levels were 26.3+/-4.1 and 13.9+/-1.4 ng/ml (P=0.004), before and after infliximab treatment, respectively. No significant correlation between the changes of BMI, C-reactive protein or the clinical indices of activity and alterations of the examined adipokines was found. CONCLUSIONS: Serum levels of leptin and adiponectin had no significant alterations, whereas serum-resistin levels are significantly decreased after infliximab therapy in IBD patients, suggesting a possible proinflammatory status for resistin in IBD and a role as a marker of successful therapy.
34
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
Stephen B. Hanauer, Brian G. Feagan, Gary R. Lichtenstein et al. · The Lancet · 2002 · 4.2K citations
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
Paul Rutgeerts, William J. Sandborn, Brian G. Feagan et al. · New England Journal of Medicine · 2005 · 3.9K citations · Full text
Development of a Crohn's Disease Activity Index
William R. Best, Jack M. Becktel, John W. Singleton et al. · Gastroenterology · 1976 · 3.2K citations
Veterinary Medicine, Clinical Sciences, Internal Medicine +12